Cargando…

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

PURPOSE: Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may fail because of difficulties within the testing procedure. Optimization of screening techniques may reduce failure r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chi, Kim N., Barnicle, Alan, Sibilla, Caroline, Lai, Zhongwu, Corcoran, Claire, Barrett, J. Carl, Adelman, Carrie A., Qiu, Ping, Easter, Ashley, Dearden, Simon, Oxnard, Geoffrey R., Agarwal, Neeraj, Azad, Arun, de Bono, Johann, Mateo, Joaquin, Olmos, David, Thiery-Vuillemin, Antoine, Harrington, Elizabeth A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Clinical Trials: Targeted Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811161/ https://www.ncbi.nlm.nih.gov/pubmed/36043882 http://dx.doi.org/10.1158/1078-0432.CCR-22-0931

Ejemplares similares

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
por: Matsubara, Nobuaki, et al.
Publicado: (2023)

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)
por: Puhalla, Shannon L., et al.
Publicado: (2021)

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study
por: Turner, Nicholas C., et al.
Publicado: (2021)

Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
por: Lee, Jung-Min, et al.
Publicado: (2022)

Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
por: Wu, Xiaohua, et al.
Publicado: (2022)

Wip1 and ATM in tumor evolution: role for BRCA1
por: Filipponi, Doria, et al.
Publicado: (2013)

Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations
por: Kim, Kyung Hwan, et al.
Publicado: (2022)

Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort
por: Li, Jingmei, et al.
Publicado: (2018)

Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor
por: Anderson, Peter M., et al.
Publicado: (2022)

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
por: Choudhury, Atish D., et al.
Publicado: (2022)

Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells
por: Wang, Zhixiong, et al.
Publicado: (2020)

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
por: Schram, Alison M., et al.
Publicado: (2022)

A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
por: Banerjee, Susana, et al.
Publicado: (2022)

Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors
por: Chi, Ping, et al.
Publicado: (2022)

Effects of Rapamycin Combined with Cisplatin on Tumor Necrosis Factor TNF-α in MG-63 Cells
por: Han, Tian-Yu, et al.
Publicado: (2020)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
por: Harding, James J., et al.
Publicado: (2021)

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
por: Brase, Jan C., et al.
Publicado: (2021)

Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
por: van Linde, Myra E., et al.
Publicado: (2022)

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
por: Joensuu, Heikki, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors
por: Takahashi, Shunji, et al.
Publicado: (2021)

Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
por: George, Suzanne, et al.
Publicado: (2022)

Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
por: Casanova, Michela, et al.
Publicado: (2023)

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
por: Johnson, Melissa, et al.
Publicado: (2022)

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
por: Yap, Timothy A., et al.
Publicado: (2021)

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
por: Bauer, Sebastian, et al.
Publicado: (2021)

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
por: Munster, Pamela N., et al.
Publicado: (2022)

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
por: Sato, Jun, et al.
Publicado: (2022)

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
por: Maitland, Michael L., et al.
Publicado: (2021)

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
por: Boni, Valentina, et al.
Publicado: (2022)

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
por: Saleh, Mansoor N., et al.
Publicado: (2021)

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
por: Tap, William D., et al.
Publicado: (2022)

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
por: Stein, Eytan M., et al.
Publicado: (2022)

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
por: Lim, Emerson A., et al.
Publicado: (2022)

Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
por: Roschewski, Mark, et al.
Publicado: (2023)

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
por: Subbiah, Vivek, et al.
Publicado: (2021)

BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis
por: Li, Qianyan, et al.
Publicado: (2021)

Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
por: Li, Jian, et al.
Publicado: (2022)

An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice
por: Ellison, Gillian, et al.
Publicado: (2017)

The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial
por: Zhao, Jimmy L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ot846t2o5k2ombabhl1907b2pe